- Home
- GOSS vs SABA Comparison
GOSS vs SABA Comparison
Compare GOSS & SABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- SABA
- Stock Information
- Founded
- GOSS 2015
- SABA 1988
- Country
- GOSS United States
- SABA United States
- Employees
- GOSS N/A
- SABA N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- SABA
- Sector
- GOSS Health Care
- SABA
- Exchange
- GOSS Nasdaq
- SABA Nasdaq
- Market Cap
- GOSS 262.5M
- SABA 246.4M
- IPO Year
- GOSS 2019
- SABA N/A
- Fundamental
- Price
- GOSS $1.21
- SABA $9.30
- Analyst Decision
- GOSS Strong Buy
- SABA
- Analyst Count
- GOSS 3
- SABA 0
- Target Price
- GOSS $7.33
- SABA N/A
- AVG Volume (30 Days)
- GOSS 2.6M
- SABA 290.0K
- Earning Date
- GOSS 08-11-2025
- SABA 01-01-0001
- Dividend Yield
- GOSS N/A
- SABA 12.91%
- EPS Growth
- GOSS N/A
- SABA N/A
- EPS
- GOSS N/A
- SABA N/A
- Revenue
- GOSS $124,590,000.00
- SABA N/A
- Revenue This Year
- GOSS N/A
- SABA N/A
- Revenue Next Year
- GOSS $91.14
- SABA N/A
- P/E Ratio
- GOSS N/A
- SABA N/A
- Revenue Growth
- GOSS N/A
- SABA N/A
- 52 Week Low
- GOSS $0.66
- SABA $3.64
- 52 Week High
- GOSS $1.55
- SABA $4.42
- Technical
- Relative Strength Index (RSI)
- GOSS 46.78
- SABA 75.41
- Support Level
- GOSS $1.20
- SABA $9.00
- Resistance Level
- GOSS $1.33
- SABA $9.18
- Average True Range (ATR)
- GOSS 0.10
- SABA 0.14
- MACD
- GOSS -0.02
- SABA 0.02
- Stochastic Oscillator
- GOSS 6.12
- SABA 100.00
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About SABA Saba Capital Income & Opportunities Fund II Shares of Beneficial Interest
Saba Capital Income & Opportunities Fund II is a closed-end fund. The company seeks high current income, with a secondary goal of capital appreciation. The fund invests in fixed income markets across the globe.